Stockscreener 앱 받기
10.59
10.62%
-1.275
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop - GuruFocus
Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com
Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - Seeking Alpha
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic - Asianet Newsable
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView
Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus
CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire
FDA Fast-Tracks Revolutionary DMD Heart Treatment as Capricor Clears Major Regulatory Hurdle - Stock Titan
Barclays PLC Has $1.24 Million Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co. - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus Target Price from Analysts - Defense World
Wells Fargo & Company MN Sells 4,641 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ: CAPR) Stock Gained 34.46% Over A Month – Any Room To Run? - Marketing Sentinel
Capricor Therapeutics Inc (CAPR) shows promising results - uspostnews.com
Capricor Therapeutics Inc (CAPR) receives an Overweight rating from Piper Sandler - knoxdaily.com
Legal & General Group Plc Grows Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Capricor Therapeutics Inc’s Market Journey: Closing Weak at 12.83, Down -1.53 - DWinneX
Russell Investments Group Ltd. Grows Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc [NASDAQ: CAPR] Sees Increase in Stock Value - knoxdaily.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Holdings Increased by Geode Capital Management LLC - Defense World
13,280 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Alliancebernstein L.P. - Defense World
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... By GuruFocus - Investing.com Canada
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges and Strategic Advancements - GuruFocus
Former Novartis Deal Chief Who Led 50+ Strategic Transactions Joins OmniAb Board - Stock Titan
Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long - simplywall.st
Stock Traders Purchase High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR) - Defense World
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable? - Yahoo
Wellington Management Group LLP Invests $565,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Vanguard Group Inc. Purchases 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Corebridge Financial Inc. Has $251,000 Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
KLP Kapitalforvaltning AS Invests $91,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World
(CAPR) Trading Advice - news.stocktradersdaily.com
Teacher Retirement System of Texas Buys Shares of 10,243 Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day - The Manila Times
Promising DMD Treatment Update: Capricor CEO Reveals Latest Development Progress - Stock Titan
Capricor Therapeutics Plunges 19.91% Amid Clinical Trials Focus - AInvest
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR) - simplywall.st
Check Out What Whales Are Doing With CAPR - Benzinga
High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st
(CAPR) Trading Signals - Stock Traders Daily
Bank of New York Mellon Corp Purchases 20,638 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor projects FDA priority review decision for deramiocel by August 2025 - MSN
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - Benzinga
Cantor Fitzgerald maintains $30 target on Capricor stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $30 target on Capricor stock - Investing.com
0.52%
0.52%
자본화:
|
볼륨(24시간):